Engin Atilla, Altan Nilgun, Isik Erdal
Department of General Surgery, Faculty of Medicine, Gazi University, Ankara, Turkey.
Drugs R D. 2005;6(1):35-40. doi: 10.2165/00126839-200506010-00004.
Lithium, widely used in the prophylaxis of psychiatric patients with bipolar affective disorders, is well known to induce thyroid alterations. However, a possible metabolic linkage between blood thyroxine levels and its regulatory function on erythrocyte glutathione concentration has not yet been evaluated in lithium-treated patients. The aim of this study was to assess the antioxidative capacity of erythrocytes in lithium-induced hypothyroidism before and after thyroxine replacement.
Thyroid ultrasound with clinical and laboratory evaluation of thyroid function and thyroid-stimulating hormone assay were performed prior to and at 6-month intervals during lithium prophylaxis in 76 patients with bipolar affective disorders. The daily lithium dosage was adjusted to 600-1200 mg and the mean duration of treatment was 2.2 +/- 0.4 years. Final assessment revealed that 12 patients had evidence of primary hypothyroidism, and these were assigned as the test group. Lithium prophylaxis was supplemented with thyroxine at a dosage of 100 mg/day within 6 months after thyroid dysfunction was diagnosed. Red blood cell superoxide dismutase activities and the glutathione contents were measured before and after thyroxine replacement. In order to assess the effect of long-term lithium administration on red blood cell glutathione and superoxide dismutase levels, 12 patients who had not developed hypothyroidism during the follow-up period were selected for the lithium-treated euthyroid group. Mann Whitney U-test and Wilcoxon rank sum W-test were used for comparison of data.
A comparison of the lithium-treated test group with healthy volunteers and their own values after thyroxine replacement revealed a significant decrease in red blood cell glutathione concentrations (p = 0.000) in the hypothyroid state. However, no clinically significant changes were observed in red blood cell superoxide dismutase activities of the test group. A statistical survey also demonstrated that there was no significant difference in the thyroid-stimulating hormone values as well as the red blood cell glutathione contents or superoxide dismutase activities between healthy controls and lithium-treated euthyroid subjects.
It is most likely that lithium primarily inhibited hormone production in the thyroid and that this led to a compensatory increase in thyroid-stimulating hormone secretion with a significant decrease in the red blood cell glutathione content. While the red blood cell glutathione content of hypothyroid patients was reduced to 40% of the post-thyroxine level, unchanged superoxide dismutase activity might render the erythrocytes vulnerable to oxidative stress and ultimately haemolysis. Thyroxine replacement during lithium prophylaxis of psychiatric patients is advisable in order to prevent subclinical hypothyroidism and related defects of erythrocyte antioxidant capacity.
锂广泛用于双相情感障碍精神病患者的预防治疗,已知其可引起甲状腺改变。然而,在接受锂治疗的患者中,血液甲状腺素水平与其对红细胞谷胱甘肽浓度的调节功能之间可能存在的代谢联系尚未得到评估。本研究的目的是评估甲状腺素替代治疗前后锂诱导的甲状腺功能减退患者红细胞的抗氧化能力。
对76例双相情感障碍患者在锂预防治疗前及治疗期间每隔6个月进行甲状腺超声检查,并进行甲状腺功能的临床和实验室评估以及促甲状腺激素测定。每日锂剂量调整为600 - 1200 mg,平均治疗时间为2.2±0.4年。最终评估显示12例患者有原发性甲状腺功能减退的证据,这些患者被分配为试验组。在诊断出甲状腺功能障碍后的6个月内,以每日100 mg的剂量补充甲状腺素进行锂预防治疗。在甲状腺素替代治疗前后测量红细胞超氧化物歧化酶活性和谷胱甘肽含量。为了评估长期锂给药对红细胞谷胱甘肽和超氧化物歧化酶水平的影响,选择12例在随访期间未发生甲状腺功能减退的患者作为锂治疗的甲状腺功能正常组。采用曼 - 惠特尼U检验和威尔科克森秩和W检验对数据进行比较。
将锂治疗的试验组与健康志愿者以及甲状腺素替代治疗后的自身值进行比较,发现甲状腺功能减退状态下红细胞谷胱甘肽浓度显著降低(p = 0.000)。然而,试验组红细胞超氧化物歧化酶活性未观察到临床上显著的变化。一项统计调查还表明,健康对照组与锂治疗的甲状腺功能正常受试者之间的促甲状腺激素值、红细胞谷胱甘肽含量或超氧化物歧化酶活性没有显著差异。
锂很可能主要抑制甲状腺激素的产生,这导致促甲状腺激素分泌代偿性增加,同时红细胞谷胱甘肽含量显著降低。虽然甲状腺功能减退患者的红细胞谷胱甘肽含量降至甲状腺素治疗后水平的40%,但超氧化物歧化酶活性未改变可能使红细胞易受氧化应激影响并最终导致溶血。在精神病患者锂预防治疗期间进行甲状腺素替代治疗是可取的,以预防亚临床甲状腺功能减退和相关的红细胞抗氧化能力缺陷。